This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
Public ClinicalTrials.gov record NCT03207750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Study identification
- NCT ID
- NCT03207750
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,280 participants
Conditions and interventions
Conditions
Interventions
- Rotarix Biological
- Pediarix Biological
- Hiberix Biological
- Prevenar 13 Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Weeks to 12 Weeks
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2017 (Actual)
- Primary completion
- Oct 9, 2018 (Actual)
- Completion
- Mar 1, 2019 (Actual)
- Last update posted
- Dec 29, 2020
2017 – 2019
United States locations
- U.S. sites
- 47
- U.S. states
- 21
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35205 | — |
| GSK Investigational Site | Fayetteville | Arkansas | 72703 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Daly City | California | 94015 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80922 | — |
| GSK Investigational Site | Altamonte Springs | Florida | 32701 | — |
| GSK Investigational Site | Boynton Beach | Florida | 33435 | — |
| GSK Investigational Site | Miami | Florida | 33142 | — |
| GSK Investigational Site | Tampa | Florida | 33617 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Frederick | Maryland | 21702 | — |
| GSK Investigational Site | Fall River | Massachusetts | 02721 | — |
| GSK Investigational Site | Bingham Farms | Michigan | 48025 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68504 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68505 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68522 | — |
| GSK Investigational Site | Syracuse | New York | 13202 | — |
| GSK Investigational Site | The Bronx | New York | 10468 | — |
| GSK Investigational Site | Boone | North Carolina | 28607 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Cleveland | Ohio | 44121 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Dayton | Ohio | 45414 | — |
| GSK Investigational Site | Dayton | Ohio | 45419 | — |
| GSK Investigational Site | Grove City | Ohio | 43123 | — |
| GSK Investigational Site | Hermitage | Pennsylvania | 16148 | — |
| GSK Investigational Site | Charleston | South Carolina | 29407 | — |
| GSK Investigational Site | North Charleston | South Carolina | 29406-9170 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Fort Worth | Texas | 76107 | — |
| GSK Investigational Site | Galveston | Texas | 77555 | — |
| GSK Investigational Site | Tomball | Texas | 77375 | — |
| GSK Investigational Site | Kaysville | Utah | 84037 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Murray | Utah | 84107 | — |
| GSK Investigational Site | Orem | Utah | 84057 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Roy | Utah | 84067 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | Syracuse | Utah | 84075 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03207750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03207750 live on ClinicalTrials.gov.